The metastatic patterns of osteosarcoma. by Jeffree, G. M. et al.
Br. J. Cancer (1975) 32, 87
THE METASTATIC PATTERNS OF OSTEOSARCOMA
G. M. JEFFREE, C. H. G. PRICE AND H. A. SISSONS*
From the Bristol Bone Tumour Registry, Bristol Royal Infirmary, Bristol BS2 8HW and the
Royal National Orthopaedic Ho8pital*, 234 Great Portland Street, London WIN 6SD
Received 3 February 1975. Accepted 14 March 1975
Summary.-The paper presents a detailed comparison ofthe anatomical distribution
and frequency of clinically evident metastases in 152 cases of osteosarcoma, and
autopsy findings in 43 cases. The behaviour of long bone tumours is contrasted
with those arising elsewhere, which tend to metastasize less widely because of early
death from effects of the primary tumour. In both clinical and autopsy series
long bone tumours produced lung metastases (LM) in over 90% of patients dying
with metastases, but the terminal frequency of extra-pulmonary metastases (EPM)
rises from a clinical level of 33% to 83% at autopsy.
There was little difference between tumours of the major long bones in the
frequency of either LM or EPM, but EPM from the humerus tended to be fewer
and sited above the diaphragm and from the femur below it. EPM most often
involved other bones, notably vertebrae and pelvis. Not more than 10% of tumours
invaded regional lymph nodes but terminally a quarter of the long bone tumours
had metastasized to heart and abdomen. The infrequency of metastases in muscle
was confirmed.
The median time for LM was 5-6 months after starting treatment, for EPM 9-10.
months. First metastases after 24 months were infrequent, especially in children.
With delay in the appearance of metastases, whether LM or EPM, post-metastatic
survival lengthened. Neither age, sex nor mode of treatment ofthe primary notably
affected metastatic frequency, although recurrences were much more numerous
when radiotherapy, even with high dosage, was the definitive treatment. Local
recurrence usually appeared within 6-8 months and was shown to lead to increased
frequency of osseous metastases. It is suggested that terminal dissemination may
often be tertiary but not always from a pulmonary secondary.
THE PAST 30 years' experience of
the treatment of osteosarcoma shows
universally bad results for any large
series of cases. This is due both to the
intrinsic limitations of current therapeutic
methods and to concentration upon con-
trol or destruction of the primary tumour
only, although it becomes increasingly
obvious that the overwhelming lethal
factor is distant metastatic growth, parti-
cularly in the lungs. With tumours
of long bones, which comprise the great
majority of osteosarcomata presenting
in young people, lung secondaries are
almost invariably the cause of death,
even though metastases in other sites
are not infrequent and are also potentially
lethal.
The explosion in diversity and scope
of chemotherapy in the last decade
is already producing better prognoses
for some solid tumours. It is hoped
that the use of cytotoxic drugs in the
treatment of osteosarcoma may prolong
the disease-free survival in this tumour
also. Planned treatment along these lines
requires a precise knowledge of tumour
behaviour, especially of the dominating
metastatic activity. We present an ana-
lytical study of the metastatic patterns
of osteosarcoma arising in otherwise
normal bones, as found both clinicallyG. M. JEFFREE, C. H. G. PRICE AND H. A. SISSONS
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and at autopsy. The full range of such
metastases is shown in Fig. 1.
PATIENTS AND METHODS
Clinical evaluation of metastases (Fig. 2,
Tables I and VII)
The records used for this study are
essentially the same as for a previous paper
(Price and Jeffree, 1973), namely the clinical
records and radiographs of 124 consecutive
cases of osteosarcoma of long bones and
28 cases of osteosarcoma of other bones
registered with the Bristol Bone Tumour
Registry (BTR). The term " other bones "
is used for all primary sites but the long
bones of the limbs. Three cases-one long
bone tumour and 2 of other bones-were
not included in the previous study. As
a few patients have died or developed
metastases over the past year, there may be
some apparent discrepancies in the data.
Though the recorded information may be
extremely meagre and clinical data are
therefore minimal, the authors have tried
to get the fullest possible information on
the progress of all patients and the times
of first clinical or radiographic evidence
of all metastases.
Metastases found at autopsy (Fig. 3, Tables
III and VIII)
Only 10 of the BTR patients came to
autopsy. One died from coronary artery
disease 12 years after high thigh amputation
for a tumour of lower femur: no evidence
of tumour was found at autopsy. In the
other 9 cases-6 osteosarcomata of long
bones and 3 of other bones-the clinical
evidence of metastases may be compared
with the autopsy findings (Fig. 3). More
autopsy records were obtained by courtesy
of a number of centres, most notably the
Cancer Research Campaign Bone Tumour
Panel in London. Information from 29
cases of osteosarcoma of long bones in which
metastases were found is given in Table III,
and from 14 tumours of other bones which
either produced metastases or where death
was due to the primary tumour in Table
VIII. There was rarely sufficient clinical
information for comparison with the autopsy
records in individual cases and so comparison
has had to be made of the overall incidence
of metastases with any given site on clinical
and autopsy evidence. That this has some
validity may be deduced from the very
similar figures obtained in the 2 series for
pulmonary metastases from the long bone
tumours, and for death due to effects of
the primary tumour in other sites. It
cannot be assumed that they are entirely
comparable since some autopsies may have
been carried out on account of unusual
clinical findings or unexpected death, which
might be referable to metastases in obscure
sites.
RESULTS
Lung metastases (LM) and extra-pulmonary
metastases (EPM) from osteosarcoma of
long bones
The clinical data are shown in Fig. 2
and 4 and Table I.
Of 124 patients, 91 (73%) had clinic-
ally evident metastases, 84 (68%) had
clinically evident LM and 30 (24%) had
clinically evident EPM.
Both LM and EPM occurred in the
same case in 23 (19%), leaving 61 (49%)
with LM only and 7 (5%) with only
EPM. Of the 91 patients dying with
metastases, 30 (33%) had evident EPM
but the autopsy records (Table III)
show a frequency of EPM at death of
83%. Thus radical or palliative treat-
ment for EPM will be required in 33-83%
of cases with metastases, approaching
the higher figure sub-terminally.
Table I shows the anatomical dis-
tribution of clinical metastases, and data
from 29 autopsies are given in Table III.
Table II summarizes the clinical incidence
ofLM and EPM from tumours ofdifferent
sites. The site of the primary tumour
does not materially affect the frequency
of metastases but the frequency of clinical
EPM is greatest for the femur, with a
tendency to more widespread dissemina-
tion and involvement of other bones,
particularly pelvis and spine, which is
also apparent in the autopsy records.
Figure 4 showsthe time ofpresentation
ofclinical metastases. The vast majority,
both LM and EPM, appeared within
2 years of starting treatment, with a
median of 5-6 months for LM and 9-10
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PRIMARY TUMOURS
FEMUR proximal 2
diaphyseal 2
distal 50
TIBIA proximal 22
distal 1
FIBULA proximal 4
TARSUS I
HUMERUS prox. 10
diaphyseal 1:
FiG. 2.-Clinical metastases from osteosarcoma-2 tumours of leg; 11 tumours of arm.
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at autopsy only
FIG. 3 Metastases from osteosarcoma, clinically manifest and found at autopsy; 6 ttumours of
long bones: 3 of other sites.
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TABLE II.-Osteosarcoma of Long Bones.
Primary Sites and Frequency of Clinical
Lung Metastases and Extra-pulmonary
Metastases (BTR)
Primary
Femur
Tibia
Fibula
All leg bones
Humerus
All long bones
Cases
68
32
5
105
19
124
Lung
metastases
48 (70%)
22 (68%)
4 (80%)
74 (70%)
10 (52%)
84 (68%)
Extra-pulmonary
metastases
21 (31%)
5 (16%)
1 (20%)
27 (26%)
3 (16%)
30 (24%)
months for EPM. However, Table IV
shows that, though the majority of pa-
tients dying from pulmonary metastases
never have clinically apparent EPM, yet
among those who do LM were noted first
in only a third of the cases (10130).
This suggests that a high proportion
of clinical EPM are true secondaries;
and this is supported by the tendency
of osteosarcoma in some bones to meta-
stasize to favoured sites (e.g. from distal
femur to pelvis). Moreover, the recur-
rence or persistence of primary tumours,
though it has little effect on the incidence
of LM, markedly increases the liability
to metastases in bone (Fig. 8). None
of these observations can be explained
PULM
on the basis of tertiary deposits in bones
from pulmonary secondaries. Neverthe-
less, the high proportion of EPM found
at autopsy (Table III), and most notably
those in a range of viscera, including the
heart, suggests that tertiary spread does
occur sub-terminally.
Post-metastatic survival
All 91 patients with clinical metastases
died but 11 lived for more than 18 months
after their metastases were apparent,
and in 8 of these their LM presented
after the median time of 5-6 months,
Among 42 patients with early metastases.
apparent before 5 months (Fig. 4), there
were only 4 long survivors (over 24
months), 2 ofwhom received specific treat-
ment (one lobectomy, one radiotherapy
+ chemotherapy). The mean total
survival time for the other 38 cases with
early metastases was only 7-2 months.
Thirty patients with EPM had aII
average survival of 6 6 months after
the EPM were observed. The best prog-
nostic situation appears to be where
EPM are confined to lymph nodes.
Three such patients sturvived 7, 33 anid
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TABLE IV. Time Sequence of Metacstases and Post-Metastatic Survivalfrom
Tumourns ofLong Bones (BTR)
Group
A. LM only
B. LM pre EPM
C. LM and EPM synchronous
D. LM post EPM
E. EPM only
No.
61
10
7
6
7
Mean age
at onset
in years
22 -1
25-5
15-9
14-7
29-3
Meani survival
in months
Post LM Post EPM
8 - 1
11 1
4-4
8-5
4-2
4-4
14-7
6-6
LM Lung metastases.
EPM Extra-pulmonary metastases.
44 months respectively from the time
of first treatment of primary tumours
of proximal humerus (1) and distal
femur (2). These 3 cases were all in
Group D of Table IV and largely account
for the long survival after EPM in that
group. The mean survival post EPM
of the other three in Group D was 8-3
months. The post-metastatic survival of
7 patients with EPM only was no better
than of those with EPM and LM, but
all these 7 had metastases in vertebrae
or pelvis or both. The prognosis for
a patient with an osseous metastasis is no
better than of one with a primary tumour
in the same site.
Sixteen patients had clinical EPM in
a single site only: 3 cases each in pelvis,
vertebrae, other long bones and lymph
nodes; 2 in brain, and one each in abdo-
men and skull. In none, however, would
any possible radical surgery for these
metastases have been a curative measure
as judged by subsequent histories. The
somewhat longer duration of life after
EPM when these precede LM or appear
alone (Table IV, Groups D and E)
emphasizes the rapidly fatal effect of lung
metastases.
LM (with or without EPM) were
recorded for 84 patients. Table V shows
the relationship between the time when
they were first noted and the mean further
survival of patients. This is also shown
for both LM and EPM in Fig. 5. Meta-
stases which appear late, although eventu-
ally lethal, are more slowly fatal. Pa-
tients with over 12 months post-metastatic
TABLE V. The Behaviour of Lung Meta-
stases from Osteosarcoma of Long Bones
(BTR)
Month when
LM first
noted
0
1-6
7-12
13-18
19-24
Over 24
No. of
cases
7
41
16
6
5
6
Survival after lung
metastases noted,
in months
A
Range Mean
3-12 6-1±3-1
1-18 5-0±3- 9
2-26 8-6±7-3
5-35 10-5±12-0
7-25 14-6±8-9
11-19 13-7±2-8
3 patients were excluded from this table:
1 with lobectomy at 46 months.
I with radiotherapy to chest at 60 months.
with fatal diabetic coma at 24 months.
survival may be grouped as follows:
Of those with LM under 6 months
post treatment 6%.
Of those with LM 6-12 months post
treatment 18 0.
Of those with LM 12-24 months post
treatment 33o.
Of those with LM over 24 months
post treatment-500.
None of the 81 patients in Table V
were recorded as having any significant
anti-metastatic treatment.
The mean survival also after EPM
were noted gradually increased with their
later manifestation (Fig. 5, Table VI).
It is, however, always less than the
mean survival post LM for the same
category. This is probably due to the
fact that in 16/30 of these patients,
LM were present either before or at the
same time as EPM, and it is the LM
which are usually lethal. Patients with
later metastases also tended to have
Primary in
distal femur
30 (490)
9 (90%)
3 (43%)
3 (50%)
5 (71%)
95G. M. JEFFREE, C. H. G. PRICE AND H. A. SISSONS
81 cases with lung metastases .X
29 with extra-pulmonary metastases 0--
3 CASES EXCLUDED
WITH LUNG METASTASES
I DXR to chest
I Thoracotomy
I d. of diabetic coma
6 12 18 24 C
TIME TO APPEARANCE OF METASTASES IN MONTHS
FIG. 5. Post-metastatic survival from osteosarcoma of long bones.
a longer pre-diagnostic history of relevant
symptoms.
Late metastases after 24 months from the
start of treatment
Late LM were found in 6 cases of
tumour of long bones, with mean survival
after metastases of 13 7 months (Table
V). One of these patients also had
clinical metastases in thyroid and muscle,
and others found at autopsy. One pa-
tient was a child (M, 13, tumour of
distal femur) but late metastases are
very rare in children, only 1/46 being
recorded here. This case was treated
by radiotherapy and delayed amputation
at 13 months and metastases appeared
at 25 months. Four of the other cases
had femoral primaries, all treated by
amputation. The sixth was a tumour
of proximal fibula, which recurred after
radiotherapy and was amputated at 25
months; metastases appeared after a
further 55 months. Thus, late LM may
occur whatever form of treatment is
used and long after complete control
of the primary tumour. There were only
2 cases of late EPM, and both already
had LM, so the EPM may well have
been tertiary. There were no late EPM
recorded in children.
In 28 cases of tumours of other bones,
late LM were recorded twice, both from
relatively favourable sites, namely a
tumour of scaphoid of foot, treated by
below-knee amputation and a recurrent
osteosarcoma of rib. These 2 cases had
overall survival of 56 and 83 months
respectively. There were no late EPM.
There was a third long survivor from
tumours of other bones, from a resected
osteosarcoma of rib, who lived over
181 months without recurrence or meta-
stases. This the only case which may
be considered ;cured and it is excluded
from Table VII, which shows the distri-
bution of metastases from tumours of
other bones, and the number of patients-
just over half-who died from effects
of the primary tumour without clinical
metastases. Eighteen of these patients
were treated by radiotherapy, 7 by
surgical excision (one vertebra, one ilium,
2 mandibles, 3 ribs) and the tumour
ofscaphoid by amputation. Two patients
received no specific treatment.
U1) cnI
I-
cn
ui
a
ui
I-
(.
-J
I-
z
0
96THE METASTATIC PATTERNS OF OSTEOSARCOMA
TABLE VI.-The Behaviour of Extra-
pulmonary Metastasesfrom Osteosarcoma
of Long Bones (BTR)
Month when
EPM first
noted
0
1-6
7-12
13-24
Over 24
Survival in months
after EPM noted
No. of
cases Range Mean
1 3
10 3-7 42+L1 7
9 1-9 5-2±3-1
7 2-17 7-6±5-1
2 6-12 9-0±4-2
One case was excluded from this Table, which
had metastasis in regional lymph nodes at 3 months,
treated by radiotherapy; post EPM survival-41
months.
Time sequences of metastases from
tumours of other bones are shown in
Fig. 6. The numbers are too small
to permit detailed analysis, but the
only 2 patients with late metastases
mentioned above lived long after these
were clinically evident-one with a tumour
of rib +30 months, the other with a
tumour of pedal scaphoid +26 months.
Both had specific local treatment for
their metastases-the rib case with ortho-
voltage therapy, the other with thora-
cotomy. In the other 11 patients, sur-
vival after clinical metastases averaged
only 5 months (range 2-8 months). This
is obviously a heterogeneous group, and
the scaphoid tumour behaved more like
a long bone osteosarcoma of a distal site.
4- Qo 3- R 12 CASES WITH F
H2- ......
E 1 : t .... :.:..:..
There were only 3 children in this group.
With an average survival of only
7 months, the proportion of cases with
clinical LM (41%) is similar to those
of the long bone cases who develop LM
in that time (57/124 - 46%). Paradoxi-
cally, if the life of these patients could
be extended, the proportion showing
metastases would increase and might
equal or exceed that for the long bone
tumours, as the presence of an uncon-
trolled primary implies the continuation
of metastatic risk. Until there is com-
plete control of the primary tumour the
later treatment of osteosarcoma of cal-
varium, spine or the limb girdles is
virtually only palliative. It has been
reported by several authors that osteo-
sarcoma of mandible has a better than
average prognosis, but in this study 4 out
of 5 cases died without clinical metastases;
of autopsy cases 2/2 had LM and 1/2
had EPM (Tables VII and VIII).
Metastases found at autopsy (Tables III
and VIII)
Twenty-seven of 29 patients with
tumours of long bones had pulmonary
metastases: in only 2 of these were the
LM solitary, in each case from a femoral
primary. All 10 cases with LM from
tumours of other bones had multiple LM.
Figure 3 shows the metastases recorded
PULMONARY METASTASES
3 WITH OTHER METASTASES
a- 1 =_ 1 m ,.
0 2 4 6 8
MONTHS FROM START OF TREATMENT
FIG. 6.-Metastases from 13 cases of osteosarcoma of other than long bones.
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TABLE VII.-Anatomical Distribution of Clinical Metastasesfrom Osteosarcoma of Other
Than Long Bones (BTR)
(27 cases with clinical metastases or dead from effects of primary)
No clinical
Cases metastases Lungs
Other Other
EPM Spine bones sites
12 5 7 -
2 1 1
3 3 - -
1 - - 1 1 -
2 - 2 1 1 1
5 4 (One case reported to have generalized metastases)
1
1 1
2 2 1
7% 7% 4%
27 14 11
52% 41%
in 9 BTR patients for whom both clinical
and autopsy records are available. The
majority of LM were clinically evident;
in other viscera the predominance of
terminal events is notable. Similarly,
comparing Tables I and III, VII and
VIII, whereas the incidence of LM is
not markedly greater in the autopsy
cases, that of EPM is greatly increased,
particularly in the viscera, with metas-
stases in lymph nodes, heart and abdomen
each being found in about a quarter of
autopsies.
Heart metastases were not recorded
clinically in any of the 152 BTR cases,
but 9 examples were recorded (21%)
in 43 autopsies. All but one were derived
from long bone tumours-6 femora, one
tibia, one humerus, one vertebra. Except
in one patient, the lungs were also
involved: 7 with multiple LM and one
with a solitary metastasis in the right
lung. Cardiac metastasis appears to be
a relatively late phenomenon and is
recorded in only one of the comparatively
shortlived cases of tumours of other bones
(Table VIII). A patent foramen ovale
was noted only once, in a patient who
had only heart and lung metastases.
The right side of the heart was involved
more often than the left (6R : 3L), and
metastases were related about equally
to endocardium and epicardium. In only
3 of these 9 cases was the metastasis
described in the myocardium.
Lymph nodes were invaded by tumour
in 11/43
frequency
and other
cases (26%), with similar
from tumours of long bones
bones. In only 4, however,
was involvement of the regional nodes
reported-the sites most frequently
recorded were hilar, mediastinal, mesen-
teric and abdominal nodes.
Abdominal metastases were found in
9/43 cases (21%), with a preponderance
from tumours of long bones. This is
almost certainly the result of haemic
spread. It is frequently associated with
metastases of liver, kidney, gall bladder or
pancreas.
The frequency of osseous metastases is
well known and is shown in Tables I, III,
VII and VIII. They appear with similar
frequency from tumours of the 3 major
long bones and slightly less often from
those of axial and girdle bones. The
vertebrae and pelvis are by far the most
common metastatic sites, particularly
from osteosarcoma offemur. At autopsy
14/29 tumours of long bones (48%) and
5/14 of other bones (36%) had osseous
metastases; they are exceeded in number
only by LM. There were 3 examples
of bone metastases distal to the elbow
and knee joints-one in the ulna from
a tumour of distal femur, and metastases
in tibia and talus from a primarv of
proximal humerus. Other less common
sites found clinically were femur and
humerus (3 each), skull (2), and one each
in mandible, mastoid, rib, sternum and
sacrum. Osseous metastases are clinically
Primary
Pelvis
Sacrum
Spine
Scapula
Ribs
Jaw
Skull
Scaphoid
All
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more frequent when there has been local
recurrence of the primary (Fig. 8).
Table VIII is an analysis ofmetastatic
sites recorded for 14 autopsied cases
of osteosarcoma of other bones. Three
(21%) had no macroscopic metastases.
LM were noted in 10 (71%) and osseous
metastases in 5 (35%). The general
pattern of EPM resembles that of the
long bone tumours but at a lower level
throughout. Osseous metastases were
found only in skull, ribs and vertebrae.
One patient, not included in Table VIII,
died from a tumour embolism of the
right subclavian vein, right auricle and
pulmonary artery, post-operative after
scapulectomy, but without other meta-
stases.
Ultimate causes of death from o8teosarcoma
Most patients die at home, without
adequate medical records, and the follow-
ing information is derived from autopsy
reports. As with many forms of cancer,
the commonest terminal factor is " malig-
nant cachexia "-emaciation andasthenia,
with or without anaemia, with multiple
LM and EPM and often a large uncon-
trolled primary tumour. About 90%
have multiple bilateral LM which are
sometimes immense. Rather less than
half have pleural effusions with some
degree of lung collapse, this being com-
moner than bronchopneumonia or bron-
chitis. About a third have metastatic or
thrombotic/embolic cardiovascular disease
and about a quarter may have obstruction
or infection of the urinary tract. Other
less frequent causes of death are haemor-
rhage into a lung or pleural cavity,
septicaemia, tracheal obstruction from
tumour metastatic in the thyroid and
intestinal obstruction due to abdominal
secondaries.
Sex and age distribution and metastases
The figures given in Table IX show
no significant differences between the
sexes for metastases either from tumours
TABLE IX.-SexFrequencies of Metastases
from Osteosarcoma (BTR)
Tumours oflong
bones
Only lung metastases
Only extra-pulmonary
metastases
All lung metastases
(iEPM)
All EPM (±LM)
Tumours of other
bones
All metastases (LM and
EPM)
74 Males
34 (46%)
3 (4%)
50 Females
27 (54%)
4 (8%)
51 (66%) 33 (66%)
20 (27%) 10 (20%)
15 Males 13 Females
6 (40%) 7 (54%)
of long bones or of other bones. Age
again has little effect, at least with
tumours of long bones: Of 42 children
under 15 years, 28 had LM = 67%;
10 had EPM = 24%0 Of 82 adults over
15 years, 56 had LM - 68%; 20 had
EPM - 24%. However, in childrenEPM
were almost invariably in bone, only 3
exceptions being recorded-one each in
liver, lymph nodes and abdomen. Late
EPM, preceded by LM, occurred in 2
adults; there were no late EPM in children
and only one late LM, but 5 late LM in
adults. There were only 3 children with
tumours of other bones; one had LM;
none had EPM.
Treatment of the primary tumour and
metastases
Table X gives comparative figures
for metastases from long bone tumours
in the 3 main treatment groups. There
are no statistically significant differences.
The incidence and effect of local recurrence
Local recurrence occurred in 35 of
124 long bone sarcomata (28%). This
includes one radiotherapy case, treated
by the " Cade " method (Lee and Mac-
kenzie, 1964) where viable tumour was
found in the amputation specimen though
there was no clinical recurrence, before
or later, and 2 patients with stump
recurrence following transfemoral amputa-
tion after radiotherapy.
The average time for recurrence was
5*5 months from starting treatment (range
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TABLE X.-Treatment ofPrimary Osteosarcoma ofLong Bones and Incidence
of Metastases (BTR)
Treatment group
A1. Surgery
A2. " Cade " method
A3. Combined RT and surgery
Cases
50 (54-4*)
48 (50-2*)
20
Lung
metastases
34 (68 %)
34 (71%)
16 (80%)
Extra-pulmonary
metastases
14 (28%)
11 (23%)
6 (30%)
Dead from tumour
With Without
secondaries secondaries
38 (76%)
37 (77%) 4 (8%)
17 (85%) 1 (5%)
* Cases with insufficient information.
x 28 Tumours ot long boneswith recurrence (35-7 dead without known 2nds)
0 82 without local recurrence (87-5 dead without recorded metastases)
6 1R 18
MONTH OF RECURRENCE
FiG. 7. Recurrence of primary osteosarcoma and metastases.
2-20 months), which is similar to the
median for LM and slightly longer than
the mean recurrence time of 3-7 months
reported by Jenkin (1973). Only 2 local
recurrences occurred after 12 months.
Figures 7 and 8 compare the frequency
of metastases in 28 cases with local
recurrence and 82 without (7 patients with
and 5 without recurrence died with no
recorded metastases, and there were 2,
not included in either group, where the
primary showed no response to treatment).
There are no marked differences between
the 2 groups for the first 6 months; after
this Fig. 7 shows an increasein metastatic
frequency related to local recurrence,
and a second rise after 18 months.
Figure 8 shows thatthe difference ismainly
due to a marked increase in bone meta-
stases from tumours with recurrence.
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28 Tumours of long bones with recurrence
82 Non-recurrent tumours of long bones
(A Lu
-4
U)6
4
I-
La
uLz uJ
LU
0
4
I-
x
0
MONTHS FROM START OF TREATMENT
i-,1F
MONTH OF RECURRENCE
FIG. 8.-Recurrence of primary osteosarcoma and metastases to lung and bone.
This is statistically significant at 24
months (P < 0-05).
It would seem that nearly all meta-
stases which are clinically manifest within
6 months of starting treatment are
already seeded at that time. This in-
cludes most lung metastases but only a
small proportion of osseous metastases,
and there is prolonged dissemination so
long asactive tumourremains in the body.
Local recurrence occurred in
18/68 tumours of femur (26%)
5/32 tumours of tibia (16%)
3/5 tumours of fibula (60%)
9/19 tumours ofhumerus (47%)
(One tumour of fibula recurred after
local excision, was treated by radio-
therapy and again recurred; it was then
amputated.)
Only the difference between humerus
and tibia is statistically significant
(P < 0 02) but the greater frequency
of local recurrence in the humerus may
be attributed to the larger proportion
treated by radiotherapy, which has a
positive correlation with recurrence:
Humerus, radiotherapy (lamputa-
tion (16/19 (84%); recurrence 47%.
Femur, radiotherapy (±amputation)
40/68 (58%); recurrence 26%.
Tibia, radiotherapy (±amputation)
11/32 (31%); recurrence 16%.
It is peculiar that the humerus, with
a high local recurrence rate, has the
lowest rate of EPM, but those which
do occur are almost entirely osseous,
thus following the trend shown in Fig. 8.
Of 35 patients with recurrence, the
treatment of the primary was:
Radiotherapy 17 (48%)
Radiotherapy + limb ablation 13* (37%)
Amputation 4 (12%)
Local excision 1 only
(3%)
* 10 of these 13 had limb ablation for tumour
recurrence. In addition, the tumour of fibula with
recurrence after excision was then treated by radio-
therapy and later amputated for further tumour
activity.
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TABLE XI.-Dosage of Irradiation to Tumours ofLong Bones and Local
Recurrence (BTR)
Orthovoltage
A-
I
Period of
treat-
Dose ment Immediate Local
(roentgen) (days) Cases ablation recurrence
< 3000 3-21 6 6
3000 12-34 3 2 1
4000 23-98 6 2 4
5000
6000
7000
8000
an(1 over
14-94
53-86
17
95-120
3
2
1
2
- 3
1
1
Megavoltage
Period of
treat-
Dose ment Imm
(rad) (days) Cases ablt
< 3000 4-55 4
3000 11 -60 5
4000 22-44 4
5000
6000
7000
8000
and over
36-44
30-63
38-75
48-79
6
12
6
4
ediate Local
ation recurrence
3 1
1 3
3
6
1 3
2
23 10 10 (43%) All
8 5 (62%) All over
5000
41 5 21 (51%)
28 1 14 (50%o)
2 cases omitted who wvere given palliative irradiation of under 1000 roentgen (OVT).
4 cases omitted where dosage coul(d not be ascertained.
Of 54 patients treated by surgery, 5
had local recurrence (9u%).
Of 50 + 20 treated by radiotherapy
surgery, 30 had recurrence (43%o).
Of the 30 cases of recurrence after
radiotherapy, 10 occurred among 23 who
were treated by orthovoltage, and 20
among 40 given megavoltage therapy.
The fibula cited above was also treated
by megavoltage, making a final figure
of 21 out of 41 cases. Table XI shows
the dosage given and numbers with
local recurrence for 64 cases of long bone
tumours treated by radiotherapy. Impor-
tant variables are not only the quality
and total dosage of irradiation, but
also field sizes, the number of treatment
fractions and duration of therapy. The
scope of this paper does not permit a
detailed analysis, but it is emphasized
that regimens used at various treatment
centres varied widely. Of 28 patients
treated with less than 5000 rad or 5000 R,
14 had immediate ablation of the tumour-
bearing limb; one of these patients had
a stump recurrence after amputation for
recurrent tumour growth. Megavoltage
therapy does not appear markedly better
than orthovoltage in controlling the pri-
mary tuimour, and local recurrence may
occur even with maximum dosage of
irradiation.
The overall effect of local recurrence
on the 5-year survival rate is small, but
contributes to the poorer results of cases
treated by radiotherapy (Price and Jef-
free, 1973). 33/35 patients with recur-
rence have died (94%o), with a mean
survival of those 33 of 17-7 months.
68/87 cases without local recurrence (78%)
died of the effects of tumour (one other
patient died after 146 months with no
residual tumour) with a mean survival
of 18-8 months. There is little difference
in survival times of those who died, the
lethal factor being LM in the great
majority of cases, but all except 2 of
the cures were in cases with no local
recurrence.
With osteosarcoma of other bones,
the problem is not so much that of
recurrence as of complete inability to
control the primary tumour. Of 27
deaths from tumour (there was one
long survivor), 14 had no clinical meta-
stases; death was due to local effects
of the primary (Table VII). A similar
result is shown in the autopsy records
of 14 patients in Table VIII. The short
survival of these cases mean 7 months
All
All over
5(0(
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does not permit any* further useful
analysis.
DISCUSSION
Metastatic frequency
The inevitable appearance of lung
metastases in the majority of cases, is
well known, but perhaps the almost
equal terminal incidence of EPM is not
so widely appreciated, nor their attendant
distress to the patient, yet most patients
dying with LM will also have EPM
(Table III).
Since we know neither the duration
of tumour growth before diagnosis nor
the precise time of metastatic spread, one
cannot be certain of the significance
of time sequences of LM and EPM in
any particular patient. At the time of
diagnosis and initiation of treatment
there is no sure method of deciding
which tumour will metastasize-when
and where. The mitotic activity may
be some guide, but its evaluation is
open to technical and sampling errors,
and the most important prognostic factor
is still the extent of our ability to control
the primary tumour, which depends
mainly upon its site. It must be emphas-
ized that any anti-metastatic treatment,
to be effective, must deal with the whole
body in every case, even though the
lung metastases are of paramount im-
portance.
The time factor is important in under-
standing several aspects of tumour be-
haviour. When survival is longer than
the median time for LM (5-6 months),
clinical metastases may present which
would not otherwise be evident. Nearly
half the patients with tumours of other
bones succumb within 6 months to local
effects of tumour growth, with no overt
metastases.
As already shown by survival curves
(Price and Jeffree, 1973), after 2 years
metastatic frequency diminishes and indi-
vidual prognosis improves.
With the median time for LM at
5-6 months, the " Cade " method alone
can never cure more than 50% ofpatients.
All published series agree on this time
for LM, whether treatment has been
"Cade " or ablation.
After the median time for LM, meta-
stases are less rapidly lethal, probably
owing to their slower growth, which
may reflect enhanced host resistance
(Table V). This less aggressive behaviour
of later metastases has been reported
for other cancers-breast, thyroid, kidney
and seminoma. Ifitisduetoahost-immune
reaction, this must be systemic and
not localized to any particular organ
or type of tissue, since it holds good
not only for LM but for EPM in a number
of different sites.
Metastases in special sites
Other bones.-As with metastatic car-
cinoma, vertebrae and pelvis are most
frequently involved. Osseous metastases
were reported clinically or radiographic-
ally for 18% of the long bone tumours,
closely conforming with the 14% of
McKenna et al. (1966). Lockshin and
Higgins (1966) found 41% with bone
metastases among 22 patients dying in
hospital who were examined terminally
by radiography or autopsy. This agrees
well with the 48% reported here with
osseous metastases at autopsy. Owing
to their shorter average survival, patients
with primary tumours of other bones
show fewer osseous metastases either
clinically (7%) or at autopsy (36%).
Heart metastases.-These are subter-
minal events, being found in our series
only at autopsy; if they are secondaries,
they must grow more slowly than meta-
stases in other sites. Yet in only 2 of
9 cases did they appear to be tertiary
from lung secondaries, in the other 7
they may have been true secondaries
or tertiary from large metastases in,
for example, the pelvis. Autopsy records
suggest that, even with advanced modern
surgical techniques, it would seldom, if
ever, be possible to remove a heart
metastasis with any good hope of success.
Possibly their late effect upon cardiac
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function may rarely be misinterpreted as
drug cardiotoxicity.
Cerebral metastases.-These were re-
corded at autopsy for 3 long bone tumours
(one femur, 2 tibia), the sites involved
being respectively surface of temporal
lobe, cerebellum and left frontal lobe;
6 separate unspecified sites. Two patients
also had multiple LM. Surgical removal
of brain metastases may deserve careful
consideration in the absence of clinical
metastases elsewhere.
Muscle.-As with other cancers, the
infrequency of muscular metastases (even
in the heart) is noteworthy. Yet the
wide spectrum of metastases suggests
that tumour cells must also reach muscle,
but find the environment unsuitable for
further growth. Why this is so is not
known but it surely merits further careful
experimental investigation. The spleen
likewise is seldom involved.
Lymph node metastases.-These were
found in 26% of all autopsies, but
metastases in regional nodes in only
10% of the 29 autopsied cases of tumours
of long bones, and in only 3% of the 124
clinical records. These figures may be
compared with Schwinn and McKenna's
(1973) report of 6% of lymph node
metastases in amputation specimens. Ca-
ceres, Zaharia and Tantalean (1969) found
11.4% with lymphoid secondaries among
35 cases. None of these figures approach
the 50% frequency of lymph node inva-
sion asserted by Makai, Belan and Malek
(.1971) on lymphographic evidence.
Age and sex have little effect upon
metastatic frequency or distribution.
Local recurrence contributes very little
to the frequency of lung metastases
(Fig. 8) since most of these are probably
seeded before treatment is begun; a
supposition supported by the frequency
of early clinical LM. It is presumably
just this fact that makes the "Cade"
technique an acceptable compromise,
otherwise one might anticipate a much
worse comparison with other methods
than is found (Price and Jeffree, 1973;
Trifaud and Meary, 1972). By contrast,
the clinical appearance of osseous meta-
stases is significantly increased by local
tumour recurrence, suggesting that only
about one-third of these have been
seeded at the time of first treatment.
Similarly in Ewing's sarcoma, which
metastasizes freely to other bones, local
recurrence is often associated with further
metastatic spread (Macintosh, Price and
Jeffree, 1975).
Longer post--metastatic survival after
later metastases (Fig. 5)
This relationship agrees with the
similar findings of Joseph, Morton and
Adkins (1971) who noted positive cor-
relations between the time of onset
of metastases, the estimated tumour
doubling time, and length of survival.
Mode of spread
The general pattern found in both
clinical and autopsy studies supports the
present view that the venous pathway
of tumour dissemination is usual. Bear-
ing in mind that in addition to the
caval vessels there is a wide network
of the vertebral vein system (Batson,
1957) in which reversal of blood flow
may take place, it is easy to comprehend
how limb tumours may spread to the
axial and girdle bones and elsewlhere.
There is some indication that leg tumours
tend to metastasize below the diaphragm
and arm tumours above it, and that
osteosarcoma of humerus is less likely
to metastasize than that of femur, but
secondaries from either limb may appear
almost anywhere. Osteosarcoma ofother
bones conforms to the long bone pattern
apart from the short time available in
most cases for the spread and growth of
metastases.
The strategy of therapy
To what extent can this study assist in
planning treatment?
1. All cases of osteosarcoma must
be regarded as systemic disease, the
majority of tumours having already
spread beyond the primary site at the
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time of diagnosis. Lung metastases in
particular must usually be seeded by this
time, though they may occasionally lie
dormant for over 5 years after successful
amputation as in 3 BTR cases.
2. Although lung metastases are the
lethal factor for most patients, effective
anti-metastatic treatment should include
the whole body. Maybe it will be neces-
sary to employ specific intrathecal treat-
ment for the central nervous system.
3. Tumour treatment resolves into
four stages: (I) Complete control of the
primary and " prophylactic " treatment
for occult micrometastases; (II) treatment
of first metastases, including regional
lymph nodes and early local recurrence.
Lymphangiography might well be used
as well as chest radiography, and isotope
scanning of at least vertebrae and pelvis
should be more often employed; (III) pre-
vention of late metastases (over 2 years)
and (IV) treatment ofadvanced multifocal
disease.
At present most cases progress through
stages I, II and IV, but half the patients
with osteosarcoma of other bones die in
stage I with uncontrolled primaries.
4. Later-appearing metastases, both
LM and EPM, are more slowly lethal,
so merit careful assessment and active
therapy-surgery, radiotherapy and che-
motherapy, or possibly all three. Estima-
tion of the tumour doubling time from
serial chest radiographs, as advocated by
Joseph et at. (1971) may be valuable in
the selection of cases suitable for thora-
cotomy.
5. If this feature of later metastases
is related to enhanced resistance, this
might be the critical time when immuno-
therapy should be practised-not when
there is a large mass of actively growing
tumour tissue.
6. The history of one patient (BTR
3210, F. 9, osteosarcoma of humerus)
who engaged in active sports after a
forequarter amputation, suggests that
this physical exertion may have been
partly responsible for her unusually wide-
spread metastases. Patients should be
advised to avoid regular forceful exertion
for at least 3 years.
The authors emphasize their appre-
ciation of the prolonged interest and
support of numerous colleagues who by
regularly referring their cases have con-
tributed to this present series of osteo-
sarcomata. Moreover, to laboratory
workers such a study would have been
impossible without the guidance obtained
by discussion of clinical and radiological
problems with those responsible for these
aspects of the care of patients.
Likewise, thanks are due to all the
pathologists who responded to the request
for copies of osteosarcoma autopsy re-
ports, particularly to those whose post-
mortem findings have been used in this
study: Drs G. M. G. Barton, A. H.
Cameron and J. Cocker, Professors I.
Doniach and D. L. Gardner, Dr G. J.
Hardy, Professors T. F. Hewer, D. H.
Mackenzie, Drs J. S. McKinnell, G.
Meachin, A. I. D. Prentice, A. H. T.
Robb-Smith, G. A. C. Summers, the late
Dr A. L. Taylor and Dr R. F. Welch.
Further autopsy data from the files
of the London Bone Tumour Panel were
included by kind permission of the
members. Mrs J. E. Nutt rendered
invaluable services in the collection of
clinical records and radiographs also
with extensive correspondence. The Bris-
tol Bone Tumour Registry and this
work are supported by generous grants
from the Cancer Campaign for Research.
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